Company Profile
Taysha Gene Therapies Stock Price, News & Catalysts
- Ticker:
- TSHA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.16 USD (+1.78%)
Close
Last updated: September 17, 2026
1.64B USD
Market cap
Why the stock is moving
As of Sep 17, 2026, TSHA closed up 1.78% at $5.16. No new same-company headline was identified in the current news window.
Company overview
CNS Gene Therapy Focus
Taysha Gene Therapies develops adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system. Its strategy centers on one-time treatments intended to address the underlying genetic cause of disease.
Lead Rett Syndrome Program
TSHA-102 is an intrathecally delivered AAV9 gene therapy for Rett syndrome. It delivers a functional form of MECP2 and incorporates Taysha's miRARE auto-regulatory technology, which is designed to control MECP2 expression on a cell-by-cell basis.
Pivotal Development Strategy
TSHA-102 is being evaluated in the REVEAL pivotal trial and the ASPIRE study. Following discussions with the FDA, Taysha may be able to support a biologics license application using the six-month interim analysis from REVEAL.
Regulatory and Manufacturing Readiness
TSHA-102 has received multiple expedited and orphan designations in the United States, Europe, and the United Kingdom. Taysha is also conducting process-performance qualification work to establish BLA-enabling manufacturing readiness.
Future catalysts
- Completion of the BLA-enabling process-performance qualification campaign for TSHA-102 in the fourth quarter of 2026.
- Topline data from the six-month interim analysis of the REVEAL pivotal trial and FDA feedback on the TSHA-102 BLA pathway in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Taysha Gene Therapies (TSHA)?
Taysha Gene Therapies (TSHA) most recently closed at 5.16 USD, a +1.78% move versus the previous session.
What is the market cap of Taysha Gene Therapies (TSHA)?
Taysha Gene Therapies currently has a market capitalization of 1.64B USD on BioPharmSignal.
What does Taysha Gene Therapies do?
CNS Gene Therapy Focus Taysha Gene Therapies develops adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system. Its strategy centers on one-time treatments intended to address the underlying genetic cause of disease. Lead Rett Syndrome Program TSHA-102 is an intrathecally delivered AAV9 gene therapy for Rett...
On which exchange is TSHA stock listed?
Taysha Gene Therapies (TSHA) is associated with NASDAQ, United States, Biopharma.
What is TSHA-102?
Completion of the BLA-enabling process-performance qualification campaign for TSHA-102 in the fourth quarter of 2026.
Which conditions is Taysha Gene Therapies targeting with TSHA-102?
Taysha Gene Therapies is associated with genetic disease based on its company overview and current catalyst commentary.
How does Taysha Gene Therapies describe recent progress with TSHA-102?
Completion of the BLA-enabling process-performance qualification campaign for TSHA-102 in the fourth quarter of 2026.
What is Gene?
CNS Gene Therapy Focus Taysha Gene Therapies develops adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system.